Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cortex (Cor) [formerly CORX] -- Ignore unavailable to you. Want to Upgrade?

To: GR who wrote (530)	10/18/1998 3:40:00 PM
From: lloyd bashaw	Read Replies (1) \| Respond to of 1255

GR: You are correct. There is risk. At this price when the partner is announced; however, it could be a double or triple (200 to 300% gain). Risk/Reward Three human clinical safety studies have now been completed with CX516 ("AMPALEX"). In all three studies, CX516 was safe and well-tolerated on acute oral administration and, importantly, statistically-significant positive effects on memory performance were seen in healthy volunteers. I believe there is a reason for this NBC National news spot at this time.

To: GR who wrote (530)	10/18/1998 4:45:00 PM
From: Cage Rattler	Read Replies (2) \| Respond to of 1255

GR: Glad someone else is concerned about the issues you mention. Are you sure ENMD is a good parallel? Last fall you recall, it dropped along with the DOW to 50% off it's high, or to about 6-8 dollars. Subsequently it gained and surpassed it's former high rising to the mid teens. When the NY Times story was published, it quickly jumped to the 80s. Then descended through about 3 brief support levels, 40, 30, and 20 and now has regained to the mid 20s demonstrating a 50% gain from the pre-NY Times release level. ENMD has always demonstrated a positive trend. Further, there has never been the appearance of anything financially questionable arising from within ENMD. Sadly, CORX has only demonstrated a long-term downward trend -- that in spite of several very favorable, yet redundant news releases over the last 18 months. Ciao, Ted